Partner Article
Non-exec director appointment for local pharmaceutical business
A pharmaceutical company in Northumberland is the latest company in the region to recruit a non-executive director to support its strategic development.
Adam Sims will join the board at SCM Pharma, and due to his extensive experience in commercial and financial roles at Aesica, he will bring with him a wealth of knowledge to help the company’s growth.
His appointment comes in the wake of a positive period for the company, after the commencement of new projects and ongoing recruitment.
Mr Sims said: “After visiting its sterile manufacturing facility, it is certainly the finest contract manufacturing site I have ever come across and provides a solid foundation for a fantastic business.
“I am looking forward to supporting the executive team with my industry contacts, experience and knowledge to help ensure it continues to maintain its high profile, thrive as an independent business and achieve its commercial objectives.”
SCM Pharma specialises in production services for pharmaceutical, biotech and medical device companies. The business has recently also won important commercial projects for oncology products and clinical trial supplies.
Dianne Sharp, managing director at SCM Pharma said: “We are delighted to have Adam on board as he brings a great deal of expertise and market expertise that will hugely benefit our organisation.”
This was posted in Bdaily's Members' News section by Ruth Mitchell .
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular morning National email for free.
The scale-ups rocketing through our fast world
Care about the experience, not just the outcome
The rise of an alternative investor model
Bots don't beat personal business coaching
From COVID-19 to the Middle East crisis
How to build credibility in B2B marketing
Is your business ready for the trade union change?
Government 'must take its foot off businesses' throats'
Upskilling key to civil engineering's future
Why apprenticeships are becoming a strategic asset
Business growth requires the right environment
OpenAI decision a wake-up call for our tech plans